Precision BioSciences DTIL 深 滬
等待開盤 05-20 09:30:00 美东时间
6.86
-0.100
-1.44%
華盛通- 最 高6.985
- 今 開6.96
- 成交量 13.30万股
- 最 低 6.6601
- 昨 收 6.96
- 總市值 1.77亿
- 52周最高 8.82
- 市盈率 靜 --
- 換手率 0.52%
- 52周最低 3.53
- 委 比 87.20%
- 總股本 2580.22万
- 歷史最高 710.10
- 量 比 0.51
- 振 幅 4.67%
- 歷史最低 3.53
- 每 手 1
- 風險率 1.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Precision BioSciences Announces New Preclinical Data From PBGENE-DMD Program In Oral Presentation At ASGCT 2026 Annual Meeting
– New preclinical data show PBGENE-DMD drove up to a 3x higher dystrophin protein restoration in skeletal muscle and up to 12x higher in respiratory muscle in early-juvenile mice compared to late-juvenile mice ––
05-14 19:14
Precision BioSciences exits substantial shareholder role in Imugene
Imugene ( ($AU:IMU) ) has shared an announcement. Imugene Limited has disclosed...
05-12 06:57
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported strong Q1 2026 results with global revenue of $205 million, including $195 million from BRIUMVI in the U.S. The company raised its full-year 2026 revenue target to $925 million, with U.S. BRIUMVI net product revenue expected to reach $885-900 million. Q2 2026 BRIUMVI U.S. net product revenue is projected at $220 million. BRIUMVI continues to show strong demand and patient growth, with ongoing clinical developments for sub...
05-06 11:00
Precision BioSciences Q1 EPS $(0.75) Misses $(0.66) Estimate, Sales $10.838M Beat $4.050M Estimate
Precision BioSciences (NASDAQ:DTIL) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.66) by 15.38 percent. This is a 66.06 percent increase over losses of $(2.21) per
05-05 19:17
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
Precision BioSciences即将发布一季报 市场关注营收表现
临床阶段基因编辑公司Precision BioSciences（DTIL）将于周二（5月6日）盘前发布2026年第一季度财报，随后于上午9：30召开电话会议...
05-05 03:12
iECURE To Present Clinical Data From Ongoing ECUR-506 Trial Using Precision Bioscience's ARCUS Nuclease At American Society Of Gene & Cell Therapy Annual Meeting May 11-15
iECURE has licensed the ARCUS® nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.The poster presentation at SIMD will feature one-year post-treatment data from the
04-28 20:14
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Precision BioSciences Receives Clinical Trial Application Approval To Expand Ongoing Global ELIMINATE-B Clinical Trial Of PBGENE-HBV
- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel
04-15 19:11
BUZZ-Precision Bio rises after quarterly results beat estimates
BUZZ-Precision Bio rises after quarterly results beat estimates ** Shares of biotech firm Precision BioSciences DTIL.O rise 8.89% to $5.51 premarket ** Co posts Q4 profit of $1.05 per share, while analysts were expecting a loss of 54 cents per share, according to data compiled by LSEG ** Posts Q4 re
03-12 20:37
